Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8245220 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 8 Pages |
Abstract
Conclusions Pancreatic cancer is chemo-radiosensitive. The proposed pre-operative scheme is feasible, does not prevent successful surgery, and must be tested on a Phase III setting. Yet, the large proportion of tumor progression during and after chemoradiation justifies the use of more efficient drugs such as Gemcitabine, and optimized radiotherapy including new techniques such as intensity-modulated radiation therapy.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Françoise M.D., Ph.D., Nicolas M.D., Jean-Yves M.D., Ph.D., Nadine M.D., Marc M.D., Ph.D., Denis M.D., Jean-François M.D., Ph.D., Pierre-Jean M.D., Ph.D., Pascal M.D., Philippe M.D., Ph.D., Michel M.D., Ph.D., Christian M.D., Ph.D.,